Publication of Annual Report and Notice of AGM

RNS Number : 9156E

Oxford BioDynamics PLC

15 February 2018

 

15 February 2018

OXFORD BIODYNAMICS PLC

("OBD" or the "Company" or the "Group")

PUBLICATION OF ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED 30 SEPTEMBER 2017

AND

NOTICE OF ANNUAL GENERAL MEETING

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that copies of its annual report and accounts for the year ended 30 September 2017 (incorporating the Notice of Annual General Meeting) ("Annual Report") and Form of Proxy have been posted to shareholders. An electronic copy of the Annual Report will be available on its website at www.oxfordbiodynamics.com, within the Investor Relations section.

Notice of Annual General Meeting

The Company's Annual General Meeting will be held at The Fitzhugh Auditorium, Cohen Quadrangle, Exeter College, Oxford OX1 2HE at 11.00 am on Thursday 15 March 2018.

For further details please contact:

Oxford BioDynamics Plc                                                                                [phone]

Christian Hoyer Millar, CEO

Paul Stockdale, CFO

Shore Capital                                                                                                      [phone]

Broker and Nominated Adviser

Stephane Auton

Edward Mansfield

FTI Consulting                                                                                                    [phone]

Financial Public Relations Adviser

Brett Pollard

Natalie Garland-Collins

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

END

 

 

NOALLFVEFAISLIT